Standard subcutaneous dose: 1.25 to 2 mg, 45 to 60 minutes before anticipated activity
Moore said primary care doctors are trained these days to discuss obesity and potential treatments with patients who bring up the topic
Eli Lilly developed the peptide as the next step beyond dual incretin agonists such as tirzepatide, and researchers now study it across obesity, type 2 diabetes and metabolic liver disease
This dual approach allows patients to choose the communication method that best suits their lifestyle and preferences, enhancing the patient experience
Other Medications: Certain central nervous system medications used in GH stimulation tests, for example, dopamine agonists (like L-Dopa) or arginine, can affect GH release
This economical option works for non-urgent orders but requires patience